TCGA-A1-A0SP-01A-11R-A084-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 19
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.570
- E2F_TARGETS+0.560
- MYC_TARGETS_V1+0.510
- G2M_CHECKPOINT+0.490
- SPERMATOGENESIS+0.290
- ALLOGRAFT_REJECTION+0.280
- MTORC1_SIGNALING+0.270
- MITOTIC_SPINDLE+0.250
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.200
- WNT_BETA_CATENIN_SIGNALING+0.200
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.380
- ESTROGEN_RESPONSE_EARLY-0.350
- PROTEIN_SECRETION-0.280
- BILE_ACID_METABOLISM-0.250
- INTERFERON_GAMMA_RESPONSE-0.200
- UV_RESPONSE_DN-0.170
- ESTROGEN_RESPONSE_LATE-0.150
- ADIPOGENESIS-0.130
- PEROXISOME-0.130
- XENOBIOTIC_METABOLISM-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-EW-A1P8-01A-11R-A144-07 | — | E | 0.857 |
| 2 | TCGA-A8-A07O-01A-11R-A00Z-07 | — | E | 0.830 |
| 3 | TCGA-A2-A0D2-01A-21R-A034-07 | — | E | 0.825 |
| 4 | TCGA-BH-A5IZ-01A-11R-A27Q-07 | — | E | 0.818 |
| 5 | TCGA-AN-A0AT-01A-11R-A034-07 | — | E | 0.812 |
| 6 | TCGA-C8-A1HJ-01A-11R-A13Q-07 | — | E | 0.801 |
| 7 | TCGA-D8-A143-01A-11R-A115-07 | — | C | 0.800 |
| 8 | SRR35579844 | — | E | 0.798 |
| 9 | TCGA-A2-A04T-01A-21R-A034-07 | — | E | 0.796 |
| 10 | TCGA-A2-A0T0-01A-22R-A084-07 | — | E | 0.796 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.570 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.560 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.510 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.490 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.290 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.280 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.270 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.190 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.180 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.170 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.160 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.140 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.140 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.110 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.110 | Inavolisib | — uncovered |